Defining the risk of SARS-CoV-2 variants on immune protection.
Marciela M DeGraceElodie GhedinMatthew B FriemannFlorian KrammerAlba GrifoniArghavan AlisoltaniGalit AlterRama Rao AmaraRalph S BaricDan H BarouchJesse D BloomLouis-Marie BloyetGaston BonenfantAdrianus C M BoonEli A BoritzDebbie L BrattTraci L BrickerLiliana BrownWilliam J BuchserJuan Manuel CarreñoLiel Cohen-LaviTamarand L DarlingMeredith E Davis-GardnerBethany L DearloveHan DiMeike DittmannNicole A Doria-RoseDaniel C DouekChristian DrostenVenkata-Viswanadh EdaraAli H EllebedyThomas P FabrizioGuido FerrariWill M FischerWilliam C FlorenceRon A M FouchierJohn FranksAdolfo García-SastreAdam GodzikAna Silvia Gonzalez-ReicheAubree GordonBart L HaagmansPeter J HalfmannDavid D HoMichael R HolbrookYaoxing HuangSarah L JamesLukasz JaroszewskiTrushar JeevanRobert M JohnsonTerry C JonesAstha JoshiYoshihiro KawaokaLisa KercherMarion P G KoopmansBette T KorberEilay KorenRichard A KoupEric B LeGresleyJacob E LemieuxMariel J LiebeskindZhuoming LiuBrandi LivingstonJames P LogueYang LuoAdrian B McDermottMargaret J McElrathVictoria A MeliopoulosVineet D MenacheryDavid C MontefioriBarbara MühlemannVincent J MunsterJenny E MuntManoj S NairAntonia NetzlAnna M NiewiadomskaSijy O'DellAndrew S PekoszStanley PerlmanMarjorie C PontelliBarry RockxMorgane RollandPaul W RothlaufSinai SacharenRichard H ScheuermannStephen D SchmidtMichael SchotsaertStacey Schultz-CherryRobert A SederMayya SedovaAlessandro SetteReed S ShabmanXiaoying ShenPei-Yong ShiMaulik ShuklaViviana SimonSpencer StumpfNancy J SullivanLarissa B ThackrayJames TheilerPaul Glyndwr ThomasSanja TrifkovicSina TüreliSamuel A TurnerMaria A VakakiHarm van BakelLaura A VanBlarganLeah R VincentZachary S WallaceLi WangMaple WangPengfei WangWei WangScott C WeaverRichard John WebbyCarol D WeissDavid E WentworthStuart M WestonSean P J WhelanBradley M WhitenerSamuel H WilksXuping XieBaoling YingHyejin YoonBin ZhouTomer HertzDerek J SmithMichael S. DiamondDiane J PostMehul S SutharPublished in: Nature (2022)
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- copy number
- public health
- risk assessment
- health risk
- infectious diseases
- healthcare
- quality improvement
- systematic review
- study protocol
- mental health
- endothelial cells
- high glucose
- dna methylation
- electronic health record
- gene expression
- human health
- drug induced
- small molecule
- multidrug resistant
- social media
- climate change
- high resolution
- liquid chromatography